Novo Nordisk's diabetes med semaglutide shows promise in NASH. Can it deliver in phase 3?

6th May 2020 Uncategorised 0

Novo Nordisk’s popular GLP-1 injectable semaglutide—sold under the brand Ozempic as a weekly diabetes therapy—said Wednesday it had racked up encouraging mid-stage data in the hot new NASH field. Now, industry watchers are laying out their expectations for a phase 3 trial.

More: Novo Nordisk's diabetes med semaglutide shows promise in NASH. Can it deliver in phase 3?
Source: fierce